Degode has recreated a patent-protected prescription drug for the treatment of acne and rosacea (generic drug). It is the first company in the EU to launch this product in co-operation with a well-established pharmaceutical company in initially 10 European countries. The development is completed and the approval phase has begun. Due to a sophisticated formulation which is very close to the original, Degode was able to convince the EU authorities to dispense with the usually long-term and cost-intensive efficacy studies.
This means a significant competitive advantage for Degode. As a result of this unique regulatory study situation, Degode will be the first supplier within the EU
Generics by DEGODE
Was sind Generika?
Ein Film des Branchenverbandes ProGenerika
03341 589 9040